Serrated polyposis syndrome (SPS) - previously known as hyperplastic polyposis (HP), is a syndrome of unknown genetic basis defined by the occurrence of multiple serrated polyps in the large intestine and associated with an increased risk of colorectal cancer (CRC).r In addition to multiple serrated polyps, conventional adenomas of the large intestine may be part of the syndrome and their presence relates to the CRC risk. Up to 40% of individuals with SPS have a family history of CRC. Occasionally SPS can occur in more than one family member.
This risk management guideline has been developed for individuals who have NOT been diagnosed with a colorectal cancer. The care of affected individuals should be individualised based on their clinical situation, and the monitoring they need as part of their treatment and post-treatment follow up.
The risk management of an individual with a pathogenic variant in 2 or more genes that confer a predisposition to cancer should also be individualised.